This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): YM311
Description: FG-2216 is an orally active, small molecule inhibitor of Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH), an enzyme that regulates the stability and activity of HIF. FG-2216 is designed to stabilize HIF and selectively activate the body's natural process of HIF-2-mediated erythropoiesis, including the induction of endogenous EPO, the mobilization and utilization of iron stores, and suppression of the inhibitory effects of inflammatory cytokines on erythropoiesis, features essential to the formation of new oxygen-carrying red blood cells and the treatment of anemia.
FibroGen and Yamanouchi
In September 2004, FibroGen entered into an agreement with Yamanouchi Pharmaceutical Co. to license FG-2216. Under this agreement, FibroGen provides Yamanouchi exclusive rights to develop and market FG-2216 and certain other FibroGen compounds with a similar mechanism of action for the treatment of anemia in Japan. FibroGen retains rights in the rest of the world, including North America and Europe. Financial terms of the agreement were not disclosed.
Yamanouchi and Fujisawa
On April 1, 2005, Astellas Pharma was formed from a merger between Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co.
FibroGen and Astellas
In April 2006, FibroGen announced it completed an exclusive licensing agreement with Astellas Pharma that provides Astellas rights to certain FibroGen hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors for development and marketing for the treatment of anemia in Europe, Commonwealth of...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: